#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS

An initiative to establish apheresis centers: indications for and performance of lipoprotein apheresis in the Czech Republic

Czech version

Authors: Vladimír Bláha 1;  Milan Bláha 2;  Jan Piťha 3,4;  Michal Vrablík 5
Authors‘ workplace: III. interní gerontometabolická klinika LF v Hradci Králové UK a FN Hradec Králové 1;  IV. interní hematologická klinika LF v Hradci Králové UK a FN Hradec Králové 2;  Interní klinika 2. LF UK a FN Motol, Praha 3;  Laboratoř pro výzkum aterosklerózy IKEM, Praha 4;  III. interní klinika 1. LF UK a VFN v Praze 5
Published in: AtheroRev 2019; 4(1): 19-27
Category:

Overview

Lipoprotein apheresis (LA) offers one of possible methods of treatment for patients with severe hypercholesterolemia – in particular homozygous familial hypercholesterolemia (HoFH) or severe non-familial hypercholesterolemias. It involves an extracorporeal elimination methodology, belonging in broader context to therapeutic apheresis procedures. LA in combination with higher doses of statins, with ezetimibe and new drugs (mipomersen, lomitapide or monoclonal antibodies, inhibiting activity of proprotein convertase subtilisin kexin type 9 – alirocumab, evolocumab, and possibly others), is currently the most efficient method of treatment for homozygous familial hypercholesterolemia (FH) and statin-refractory patients with hypercholesterolemia (FH). To increase availability of this treatment in the Czech Republic, specialist societies engaging in therapeutic apheresis have developed the initiative to establish apheresis centers in the Czech Republic. Through the concerted efforts of the professional societies engaged (Czech Society for Atherosclerosis, Society for Transfusion Medicine, Czech Society of Nephrology, Czech VitreoRetinal Society, Czech Ophthalmological Society, Czech Neurological Society, Society for Organ Transplantation, Czech Diabetes Society, Czech Transplantation Society and Czech Dermatovenerology Society), this initiative should lead to the establishment of apheresis centers in the Czech Republic. The apheresis centers within the initiative should form a platform creating organizational and other operational conditions for their specialist activities and provide a basis for the preparation of arguments to be used in discussions with health insurance companies.

Keywords:

Atherosclerosis – cardiovascular risk – familial hypercholesterolemia – lipoprotein apheresis

Sources
  1. Stein EA. Drug and alternative therapies for hyperlipidemia. Atherosclerosis 1994; 108(Suppl): S105-S116.
  2. Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol 2010; 21(6): 487–491. Dostupné z DOI: <http://dx.doi.org/.1097/MOL.0b013e32833e13fd>.
  3. Kobayashi S, Oka M, Moriya H et al. LDL-apheresis reduces P-Selectin, CRP and fibrinogen – possible important implications for improving atherosclerosis. Ther Apher Dial 2006; 10(3): 219–223. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1744–9987.2006.00332.x>.
  4. Blaha V, Bláha M, Lánská M et al. LDL-aferéza v léčbě familiárních hyperlipoproteinemií. Vnitř Lék 2014; 60(11): 970–976.
  5. Stefanutti C, Morozzi C, Petta A. Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine. 2011; 56(3): 842–849. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cyto.2011.08.027>.
  6. Stefanutti C, Watts GH, Harada-Shiba M et al. Toward an international consensus – Integrating lipoprotein apheresis and new lipid-lowering drugs. J Clin Lipidol 2017; 11(4): 858–871.e3. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2017.04.114>.
  7. Bláha M, Krejsek J, Andrýs J et al. sP-selectin, sE-selectin and monocyte chemotactic protein-1 (MCP-1) levels during extracorporeal cholesterol elimination. In: Berger J. Cells IV (4th Conference on Cell Biology: 9th-11th September 2002, České Budějovice. Kopp 2002: České Budějovice: 177. ISBN 80–7232–181–1.
  8. Bláha M, Lánská M, Tomšová H et al. Apheresis data registration in WAA registry – 10-year experience of our center. Transfus Apher Sci 2017; 56(5): 738–741. Dostupné z DOI: <http://dx.doi.org/10.1016/j.transci.2017.08.024>.
  9. Thompson GR. Managing homozygous familial hypercholesterolaemia from cradle to grave. Atheroscler Suppl 2015; 18: 16–20. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosissup.2015.02.002>.
  10. Bláha M, Lánská M, Blaha V et al. Pregnancy in homozygous familial hypercholesterolemia – Importance of LDL-apheresis. Atherosclerosis Supplements 2015; 18: 134–139. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosissup.2015.02.024>.
  11. Rubba P, Faccenda F, Somma SD et al. Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia. Stroke 1993; 24(8): 1154–1161.
  12. Rubba P, Iannuzzi A, Postiglione A et al. Hemodynamic changes in the peripheral circulation after repeat low-density lipoprotein apheresis in familial hypercholesterolemia. Circulation 1990; 81(2): 610–616.
  13. Aengevaeren WR, Kroon AA, Stalenhoef AF et al. Low-density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996; 28(7): 1696–1704.
  14. Kitabatake A, Sato H, Hori M et al. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group. Clin Ther 1994; 16(3): 416–428.
  15. Matsuzaki M, Hiramori K, Imaizumi T et al. Intravascular ultrasound evaluation of coronary plaque regression by low-density lipoprotein-apheresis in familial hypercholesterolemia: the Low-Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 2002; 40(2): 220–227.
  16. Koga N, Watanabe K, Kurashige Y et al. Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. J Intern Med. 1999; 246(1): 35–43.
  17. Tsuchida H, Shigematsu H, Ishimaru S et al. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS). Int Angiol 2006; 25(3): 287–292
  18. Tatami R, Inoue N, Itoh H et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. Atherosclerosis 1992; 95(1): 1–13.
  19. Waidner T, Franzen D, Voelker W et al. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. Clin Investig 1994; 72(11): 858–863.
  20. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, Eisenhauer T, et al. The HELP-LDLapheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur J Clin Invest 1994; 24(11): 724–732.
  21. Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, et al. Familial Hypercholesterolemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995; 345(8953): 811–816.
  22. Kroon AA, Aengevaeren WR, van der Werf T et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93(10): 1826–35.
  23. Richter WO, Donner MG, Hofling B et al. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 1998; 47(7): 863–868.
  24. Nishimura S, Sekiguchi M, Kano T et al. Effects of intensive lipid lowering by low density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999; 144(2): 409–417.
  25. Thompson GR, Blom DJ, Marais AD et al. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J 2018; 39(14): 1162–1168. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx317>.
  26. Schwartz J, Padmanabhan A, Aqui N et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher 2016; 31(3): 149–162. Dostupné z DOI: <http://dx.doi.org/10.1002/jca.21470>.
  27. Palcoux JB, Atassi-Dumont M et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 2008; 12(3): 195–201. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1744–9987.2008.00574.x>.
  28. Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102(9): 1199–1204. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2008.06.049>.
  29. Kolansky DM, Cuchel M, Clark BJ et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102(11): 1438–1443. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2008.07.035>.
  30. Bláha M, Zadák Z, Blaha V et al. Extracorporeal LDL-cholesterol elimination (25 years of experience). Atheroscler Suppl 2009; 10(5): 17–20. Dostupné z DOI: Dostupné z DOI: <http://dx.doi.org/10.1016/S1567–5688(09)71804–5>.
  31. Thompson GR, Catapano A, Saheb S et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 2010; 21(6): 492–498. Dostupné z DOI: <http://dx.doi.org/10.1097/MOL.0b013e3283402f53>.
  32. Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998; 82(12): 1489–1495.
  33. Koziolek MJ, Hennig U, Zapf A et al. Retrospective analysis of longterm lipid apheresis at a single center. Ther Apher Dial 2010; 14(2): 143–152. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1744–9987.2009.00747.x>.
  34. Jaeger BR, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6(3): 229–239. Dostupné z DOI: <http://dx.doi.org/10.1038/ncpcardio1456>.
  35. Tesařová Š, Blaha V, Češka R et al. General characteristics of patients with homozygous form of familial hypercholesterolaemia in the Czech Republic. Atheroscler Suppl 2018; 32: 78. Dostupné z DOI: <https://doi.org/10.1016/j.atherosclerosissup.2018.04.238>.
  36. Bláha M, Cermanová M, Blaha V et al. Safety and tolerability of LDL-apheresis in familial hyperlipoproteinaemia. Therapeutic Apheresis and Dialysis 2007; 11(1): 9–15. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1744–9987.2007.00450.x>.
  37. Lánská M, Bláha M, Žák P. Extrakorporální eliminace cholesterolu u familiární hypercholesterolemie – srovnání dvou metod.Transfuze a hematologie dnes 2014; 20(3): 67–75.
  38. Winters JL.[ American Society for Apheresis]. American society for apheresis guidelines on the use of apheresis in clinical practice: Practical, concise, evidence-based recommendations for the apheresis practitioner. J Clin Apher 2014; 29(4): 191–193. Dostupné z DOI: <http://dx.doi.org/10.1002/jca.21334>.
  39. Winters JL. Low-density lipoprotein apheresis: principles and indications. Semin Dial 2012; 25(2): 145–151. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1525–139X.2011.01025.x>.
  40. Schettler V, Neumann, CL, Hulpke-Wette M et al. Current view: indications for extracorporeal lipid apheresis treatment. Clin Res Cardiol Suppl. 2012; 7(Suppl 1): 15–19. Dostupné z DOI: <http://dx.doi.org/10.1007/s11789–012–0046–6>.
  41. Fischer S, Schatz U, Julius U. Current standards in diagnosis and therapy of hyperlipoproteinemia. Atheroscler Suppl 2013; 14(1): 15–18. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosissup.2012.10.035>.
  42. Julius U. Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection. Med Devices (Auckl) 2016; 9: 349–360. Dostupné z DOI: <http://dx.doi.org/10.2147/MDER.S98889>.
  43. Stefanutti C. The 1st and the 2nd Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update. Blood Transfusion 2017; 15(1): 42–48. Dostupné z DOI: <http://dx.doi.org/10.2450/2016.0272–15>.
  44. Derfler K, Steiner S, Sinzinger H. Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. Wien Klin Wochenschr 2015; 127(15–16): 655–663. Dostupné z DOI: <http://dx.doi.org/10.1007/s00508–015–0833–4>.
  45. Makino H, Tamanaha T, Harada-Shiba M. LDL apheresis in Japan. Transfusion and Apheresis Science 2017; 56(5): 677–681. Dostupné z DOI: <http://dx.doi.org/10.1016/j.transci.2017.08.014>.
  46. Blaha V, Zadák Z, Bláha M et al. Selekční kritéria k léčbě závažných hyperlipoproteinémií metodou LDL-aferéz. Čas Lék Česk 1998; 137(14): 424–429.
  47. Blaha V, Bláha M, Lánská M et al. Postavení lipoproteinové aferézy v současnosti. Vnitř Lék 2015; 61(11): 958–964.
  48. Fridey JL, Kaplan AA. Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology. UpToDate 2018. Dostupné z WWW: <https://www.uptodate.com/contents/therapeutic-apheresis-plasma-exchange-or-cytapheresis-indications-and-technology>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Nutraceuticals with hypolipidemic effect in clinical practice: a summary statement of the International expert panel of lipidologists prepared by the committee of the Czech society for atherosclerosis
Severe mixed dyslipidemia as a manifestation of hematological disease: case report
The effect of alirocumab on cardiovascular events: What did the ODYSSEY OUTCOMES Trial show?
Lysosomal acid lipase deficiency in differential diagnosis of familial hypercholesterolemia
Therapy of dyslipidaemia in patient with muscular dystrophy: case report
Psoriasis as a risk factor for cardiovascular events: case report
Intensive management of dyslipidemia in very high-risk patients with PCSK9 inhibitors
Article was published in

Athero Review

Issue 1
2019 Issue 1
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#